Dogwood (DWTX) Therapeutics filed for new intellectual property protection for synthetic Halneuron. If granted, the IP’s exclusivity period will extend to 2045, before additional patent term restoration extensions.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DWTX:
- Dogwood Therapeutics Approves Equity Plan Amid Business Merger
- Dogwood enrolls first 100 patients in Halneuron Phase 2b trial
- Strategic Acquisitions and Promising Trials Bolster Buy Rating for Dogwood Therapeutics
- Dogwood Therapeutics Advances Pain Treatment Pipeline
- Dogwood reports Q3 EPS ($8.20) vs ($2.05) last year